Sarcolemmal Ca 2ϩ entry is a vital step for contraction of cardiomyocytes, but Ca 2ϩ overload is harmful and may trigger arrhythmias and/or apoptosis. To maintain the amount of Ca 2ϩ entry within an appropriate range, cardiomyocytes have feedback systems that tightly regulate ion channel activities in response to the changes in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ), thereby regulating Ca 2ϩ entry. In guinea pig ventricular myocytes, Ca 2ϩ ionophore, A23187, induced suppression of the L-type Ca 2ϩ currents (I Ca,L ) and enhancement of the slowly activating delayed rectifier K ϩ currents (I Ks ). At a low stimulation rate, I Ca,L suppression and I Ks enhancement contributed to the A23187-induced APD shortening with a similar magnitude, whereas at a high stimulation rate, I Ks enhancement dominantly contributed to APD shortening. I Ks enhancement induced by A23187 was attributable to actions of nitric oxide (NO), because they were inhibited by an inhibitor of NO synthase (NOS) and by a NO scavenger. A23187-induced alterations of APD and I Ks were strongly suppressed by a NOS3 inhibitor, but barely affected by a NOS1 inhibitor, suggesting that NOS3 was responsible for NO release in this phenomenon. Inhibition of calmodulin (CaM), but not Akt, blocked the enhancement of I Ks by A23187. Thus, CaM-dependent NOS3 activation confers the selective Ca 2ϩ -sensitivity on I Ks . Ca 2ϩ -induced I Ks enhancement and resultant APD shortening potentially act as a physiological regulatory mechanism of Ca 2ϩ recycling, because they were observed at a physiological range of [Ca 2ϩ ] i in cardiac myocytes and are induced by physiologically relevant Ca 2ϩ loading, such as digitalis application and rise in extracellular Ca 2ϩ concentration. (Circ Res. 2005;96:64-72.)
T o maintain the amount of Ca 2ϩ entry within a narrow range, cardiomyocytes develop feedback systems that tightly regulate ion channel activities and thereby Ca 2ϩ entry in response to the changes in intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ). The elevation of [Ca 2ϩ ] i directly regulates Ca 2ϩ entry pathway, the L-type Ca 2ϩ channel. [1] [2] [3] It also alters the duration of action potential plateau and regulates the duration where the L-type Ca 2ϩ channel can open. The slope of action potential plateau is mainly dependent on the balance between L-type Ca 2ϩ channel currents (I Ca,L ) and delayed rectifier K ϩ currents. Delayed rectifier K ϩ currents consist of two components: the rapidly activating component (I Kr ) that is sensitive to a class III antiarrhythmic drug E-4031 and the slowly activating component (I Ks ) that is E-4031-resistant. 4 Elevations in [Ca 2ϩ ] i selectively enhances the I Ks component. 4, 5 The range of [Ca 2ϩ ] i that regulates I Ks (between 10 Ϫ8 and 10 Ϫ6 mol/L) is in the range that alters during the cycle of contraction and relaxation of cardiac myocytes. 5, 6 Thus, the Ca 2ϩ sensitivity of I Ks may potentially act as a physiological feedback system to regulate [Ca 2ϩ ] i .
In a previous article, we showed that I Ks enhancement by elevation of [Ca 2ϩ ] i was inhibited by a calmodulin (CaM) inhibitor, but not by an inhibitor of CaM-dependent kinase II. 6 Although this finding suggests that the allosteric regulation of CaM is crucial for Ca 2ϩ -sensitive I Ks alterations, the detailed underlying mechanism remains unknown. Recently, we found that I Ks was enhanced by nitric oxide (NO) via a cGMP-independent mechanism. 7 Because allosteric interaction of Ca 2ϩ /CaM complex with NO synthase (NOS) is a major mechanism of NOS activation and NO release, 8, 9 we tested in the present study if NO plays an important role in the Ca 2ϩ -sensitive modulation of I Ks in cardiac myocytes.
Materials and Methods
The investigation was conducted in accordance with the rules and regulations of the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University.
Quantification of [Ca 2؉ ] i
Quantification of [Ca 2ϩ ] i was performed as described previously. 10 (See the Expanded Materials and Methods section in the online data supplement available at http://circres.ahajournals.org.) Briefly, guinea pig ventricular myocytes were loaded with 10 mol/L indo-1-AM (Dojin), and Ca 2ϩ transients were elicited by fieldstimulation at 1 Hz. Cells were excited at 360 nm from a Xenon lamp and the emission bands, 395 to 415 nm and 470 to 490 nm, were separated (W-VIEW system, Hamamatsu Photonics), detected by a high-speed cooled CCD camera (HISCA, Hamamatsu Photonics), and ratio of the intensity of two emission bands was calculated (Aquacosmos software, Hamamatsu Photonics).
Patch Clamp
Single ventricular myocytes were harvested from hearts of adult guinea pigs (nϭ41, white Hartrey; Saitama Experimental Animal Supply Co Ltd, Saitama, Japan). 11 Action potentials and membrane currents were recorded with an Axopatch 200B amplifier (Axon Instruments) using the perforated configuration of the patch-clamp technique with Amphotericin B (Sigma-Aldrich), in a current-clamp mode and a voltage-clamp mode. Action potentials were elicited by passing depolarizing current pulses (Ͻ2 ms in duration at a rate of 1 Hz) of suprathreshold intensity. I Ks were elicited by 3.5-second depolarizing pulses to various test potentials between Ϫ30 and ϩ50 mV in 10-mV increments at 0.1 Hz from a holding potential of Ϫ40 mV, and amplitudes of tail I Ks were measured by extrapolating from exponential fits. Compositions of solutions used are described in the online data supplement. All experiments were performed at 36Ϯ1°C. The averaged series resistance was 15.7Ϯ1.7 M⍀, the capacitance time constant was 2.5Ϯ0.3 ms, and the membrane capacitance was 150Ϯ13 pF.
Immunoprecipitation and Immunoblotting
Cardiomyocytes were isolated from adult guinea pigs (nϭ3), 12 and immunoprecipitation and immunoblotting were performed as described previously (see online data supplement). 13 Briefly, cell lysates were immunoprecipitated with a monoclonal anti-NOS3 antibody (Zymed), followed by immunoblot analysis with an anti-NOS3 antibody (Zymed), an anti-caveolin-3 (Cav-3) antibody (N-18, Santa Cruz Biotechnology), or an anti-CaM antibody (FL-149, Santa Cruz Biotechnology) followed by incubation with a horseradish peroxidase-conjugated anti-mouse IgG (DAKO Japan Co Ltd) or an anti-rabbit IgG (DAKO Japan Co Ltd). Proteins were detected using the advance enhanced chemiluminescence system (Amersham Bioscience).
Reagents
Chromanol 293 B was supplied by Hoechst. E-4031 was purchased from Eisai Co Ltd, A23187, W7 and W5 from Wako, SH-6 from Merck, digoxin from Nacalai tesque, and all other reagents from Sigma-Aldrich. A23187 was prepared as a 10 mmol/L stock solution in ethanol. Stock solutions of E-4031 (5 mmol/L), W7 (10 mmol/L), W5 (10 mmol/L), S-methylisothiourea (SMTU; 10 mmol/L), N-acetyl-L-cysteine (L-NAC; 100 mmol/L), S-methyl-L-thiocitrulline (SMTC; 5 mmol/L), L-N 5 -(L-lminoethyl)ornithine (L-NIO; 1 mmol/L), and sodium nitroprusside (SNP; 1 mol/L) were prepared in distilled water, and nisoldipine (10 mmol/L), SH-6 (20 mmol/L), and 2-(4-morpholinyl)-8-phenyl-1-(4H)-benzopyran-4-one hydrochloride (LY-294,002; 60 mmol/L) stock solutions in dimethylsulfoxide. They were diluted in the bath solution to achieve the desired concentration.
Data Analysis
All values are presented as meanϮSE. Statistical significance was determined by repeated-measure one-way analysis of variance (ANOVA) followed by Scheffé F test. Values PϽ0.05 are considered to be significant.
Results

Elevation of [Ca 2؉ ] i by A23187 Shortened Action Potential Duration and Enhanced I Ks
Addition of A23187 to the bath solution increased [Ca 2ϩ ] i both in the basal level and at the peak of Ca 2ϩ transient ( Figure 1A ). The basal [Ca 2ϩ ] i was 0.12Ϯ0.01 mol/L (nϭ10) in the control state, 0.16Ϯ0.03 mol/L (nϭ5) in the presence of A23187 at 0.1 mol/L (PϭNS versus control), and 0.22Ϯ0.02 mol/L (nϭ5) at 2 mol/L of A23187 (PϽ0.05 versus control). The peak [Ca 2ϩ ] i was 0.97Ϯ0.03 mol/L (nϭ10) in the control state, 1.24Ϯ0.03 mol/L (nϭ5) at 0.1 mol/L of A23187 (PϽ0.05 versus control), and 1.52Ϯ0.09 mol/L (nϭ5) at 2 mol/L of A23187 (PϽ0.05 versus control).
Application of A23187 induced a dose-dependent shortening of action potential duration and enhancement of I Ks , which attained a maximal value at a concentration of 2 mol/L of A23187 (where APD 20 shortened by 49%, APD 90 by 20%, and I Ks amplitude increased by 31%) (see online data supplement). These values are comparable to magnitude of Ca 2ϩinduced enhancement of I Ks recorded in the excised giantpatch recording. 6 Thus, in the following experiments, we used A23187 at this concentration (2 mol/L). Once electrical access in the perforated patch configuration was established, there was a slight time-dependent reduction in APD that occurred without drug application. Application of A23187 (2 mol/L) reversibly shortened both APD 20 (OE in Figure 1B ) and APD 90 (‚ in Figure 1B ) with a significantly greater magnitude than time-dependent reduction in APD without drug application (F and E in Figure 1B ) (nϭ5, PϽ0.01). Treatment with A23187 (2 mol/L) for 15 minutes shortened APD 20 by 49.4Ϯ3.3% ( Figure 1B , nϭ5, PϽ0.01 versus spontaneous APD 20 shortening), and APD 90 by 19.2Ϯ3.6% ( Figure 1B , nϭ5, PϽ0.01 versus spontaneous APD 20 shortening). The tail amplitude of I Ks in the control cells exhibited a time-dependent decrease (E in Figure 1C ). Application of A23187 (2 mol/L) reversibly increased tail I Ks by 31.2Ϯ2.3% ( Figure 1C , nϭ5, PϽ0.01 versus spontaneous time-dependent reduction in I Ks ). Addition of EGTA (10 mmol/L), a Ca 2ϩ chelator, to the pipette solution prevented shortening of APD and enhancement of tail I Ks amplitude by A23187 (see online data supplement). These results indicate that the effects of extracellularly applied A23187 on APD and I Ks are dependent on the elevation in [Ca 2ϩ ] i .
Relative Contribution of I Ks and I Ca,L to Ca 2؉ -Induced APD Shortening
I Ca,L amplitude is diminished by elevation in [Ca 2ϩ ] i via the Ca 2ϩ -induced Ca 2ϩ inactivation mechanism, which also induces APD shortening. 2, 3 To assess relative contribution of Ca 2ϩ -induced I Ks enhancement and I Ca,L inactivation to the APD shortening induced by A23187, we used a I Ks channel blocker, chromanol 293B, and/or a I Ca,L channel blocker, nisoldipine, at supramaximal concentrations. Action potentials were continuously elicited at a stimulation rate of 0.1, 0.4, 1, and 4 Hz, and after shortening of APD by A23187 (2 mol/L) had reached a pseudo-steady state, chromanol 293B (30 mol/L), nisoldipine (3 mol/L), or a combination of chromanol 293B (30 mol/L) and nisoldipine (3 mol/L) was added in the presence of A23187 (2 mol/L). At 0.1 Hz, chromanol 293B alone or nisoldipine alone partially reversed A23187-induced APD 20 and APD 90 shortening with a similar magnitude (left panel in Figure 2A ): APD 20 shortening was reversed by 49.4Ϯ3.3% by chromanol 293B and by 48.9Ϯ3.1% by nisoldipine, (nϭ5, PϭNS) ( Figure 2B ), and APD 90 shortening was reversed by 54.5Ϯ3.4% by chromanol 293B and by 42.7Ϯ3.0% by nisoldipine (nϭ5, PϭNS) ( Figure 2C ). A combination of chromanol 293B and nisoldipine completely reversed A23187-induced APD shortening to the control levels ( Figure 2B and 2C). When stimulation rate was increased to 0.4, 1, and then 4 Hz, the magnitude of APD shortening was progressively increased with progressive increases in the fraction of APD shortening reversed by chromanol 293B, leaving the fraction reversed by nisoldipine 
Roles of NO in APD Shortening and I Ks Enhancement by A23187
Ca 2ϩ is a well-known activator of NOS. 8, 9 Recently, we reported that NO increased I Ks possibly by a mechanism dependent on direct S-nitrosylation of the channel protein, 6 which prompted us to examine potential roles of NO in the A23187-induced enhancement of I Ks . After A23187 (2 mol/L) had shortened APD and enhanced I Ks , we applied a nonspecific NOS inhibitor, SMTU (1 mol/L). Effects of A23187 (2 mol/L) on APD were partially, but significantly reversed by SMTU ( Figure 3A) , and those on I Ks were fully reversed back to the control levels ( Figure 3B ). Application of a NO scavenger, L-NAC (1 mmol/L), also reversed enhancement of I Ks induced by A23187 to the control levels ( Figure 3B ). Effects of A23187 on the gating properties of I Ks were also similar to those by a NO donor, SNP, which provide supporting evidence that A23187 enhances I Ks by causing the production of NO (see online data supplement).
NOS3 Is Responsible for A23187-Induced NO Release
Increase in I Ks occurs rapidly after application of A23187, which argues against activation of inducible NOS (NOS2). Therefore, we determined whether A23187 activated NOS1 or NOS3 to cause enhancement of I Ks . We used 2 different NOS inhibitors, SMTC, which has a significantly lower IC 50 for NOS1 (0.31 mol/L) than for NOS3 (5.4 mol/L), 14 and L-NIO, which has a significantly lower IC 50 for NOS3 (0.5 mol/L) than for NOS1 (3.9 mol/L). 15 Application of SMTC (3 mol/L) did not alter enhancement of tail I Ks amplitude by A23187 (a and c in Figure 3C ), whereas L-NIO (1 mol/L) reversed A23187-enhanced I Ks to the initial levels (b and c in Figure 3C ). These findings strongly suggest that effects of A23187 on APD and I Ks occur via NO released from NOS3.
NOS3 Activation Is Dependent on CaM
NOS3 is activated via at least two distinct pathways, a Ca 2ϩ -dependent pathway involving Ca 2ϩ -binding protein CaM or a phosphorylation-dependent pathway involving Ser/Thr kinase Akt. 16, 17 We determined how A23187 activated NOS3 by using a CaM inhibitor (W7) and an Akt inhibitor (SH-6). W7 (10 mol/L) reversed enhancement of I Ks by A23187 back to the initial levels (a in Figure 4A and 4B). A chemically related but inactive analog of W7, W5, did not alter A23187-enhanced I Ks (b in Figure 4A and 4B). Neither SH-6 (10 mol/L) nor LY-294,002 (30 mol/L), an inhibitor of PI-3 kinase (an upstream activator of Akt), altered A23187-enhanced tail I Ks (c and d in Figure 4A and 4B) . Similarly, application of W7 (10 mol/L) reversed shortening of APD 20 and APD 90 by A23187 (2 mol/L) (a in Figure 4C and 4D). In contrast, SH-6 (10 mol/L) application did not reverse shortening of APD 20 or APD 90 by A23187 (b in Figure  4C and 4D).
In cardiomyocytes, NOS3 localizes into caveolae and interacts with muscle-specific caveolin, Cav-3. 18, 19 Dissociation of NOS3 from Cav-3 is a mandatory step for NOS3 activation. 20 Using cardiac myocyte lysates, we performed immunoprecipitation using a NOS3 antibody to determine its relative associations with Cav-3 or CaM. In the control condition, immunoblot with an anti-Cav-3 antibody or an anti-CaM antibody demonstrated that NOS3 was predomi-nantly associated with Cav-3 but not with CaM (lane 1 in Figure 5A and 5B). In contrast, cells treated with A23187 (2 mol/L) for 20 minutes reduced association of NOS3 with Cav-3 and increased its association with CaM (lane 2 in Figure  5A and 5B). W7 (10 mol/L) prevented changes in NOS3 association caused by A23187 (2 mol/L) (lane 3 in Figure 5A and 5B), whereas SH-6 (10 mol/L) did not alter changes in NOS3 association caused by A23187 (2 mol/L) (lane 4 in Figure 5A and 5B). These data indicate that A23187 causes NOS3 to switch its binding partner from Cav-3 to CaM.
Effects of Ca 2؉ Loading by Digoxin and Rise in Extracellular Ca 2؉ Concentration on APD and I Ks
Finally to examine if physiologically relevant Ca 2ϩ -loading also shorten APD and enhance I Ks , we examined effects of digoxin and rise in extracellular Ca 2ϩ concentration ([Ca 2ϩ ] o ). Application of digoxin at 0.2 mol/L to the bath solution did not significantly change basal [Ca 2ϩ ] i (0.10Ϯ0.01 mol/L in the control state [nϭ6] and 0.13Ϯ0.02 mol/L in the presence of digoxin at 0.2 mol/L [nϭ6]; PϭNS), whereas peak [Ca 2ϩ ] i was increased from 0.98Ϯ0.06 mol/L (nϭ6) in the control state to 1.47Ϯ0.08 mol/L (nϭ6) (PϽ0.05). Digoxin at 2 mol/L increased both basal [Ca 2ϩ ] i from 0.10Ϯ0.01 mol/L (nϭ6) in the control state to 0.20Ϯ0.01 mol/L (nϭ5) (PϽ0.05) and peak [Ca 2ϩ ] i from 0.98Ϯ0.06 mol/L (nϭ6) to 1.96Ϯ0.09 mol/L (nϭ5) (PϽ0.05) ( Figure 6A ). Digoxin at 0.2 mol/L shortened APD 20 by 28.0Ϯ3.9% and APD 90 by 12.6Ϯ3.1% relative to the control, and digoxin at 2 mol/L shortened APD 20 by 58.8Ϯ3.4% and APD 90 by 24.0Ϯ3.4% relative to the control ( Figure 6B and online data supplement). L-NAC (1 mmol/L) partially, but significantly, reversed APD shortening by digoxin ( Figure 6B and online data supplement). Digoxin at 0.2 mol/L increased I Ks amplitude by 17.4Ϯ3.1%, and digoxin at 2 mol/L by 37.7Ϯ7.1% relative to the control ( Figure 6B and online data supplement). I Ks enhancement by digoxin was fully reversed by application of L-NAC (1 mmol/L) ( Figure 6B and online data supplement).
Rise in [Ca 2ϩ ] o from the control state (1.8 mmol/L) to 2.4 mmol/L shortened APD 20 by 27.2Ϯ3.9% and APD 90 by 17.4Ϯ3.0%, and to 3.0 mmol/L shortened APD 20 by 45.4Ϯ3.8% and APD 90 by 26.7Ϯ3.2%, which were partially, but significantly reversed by L-NAC (1 mmol/L) ( Figure 6C and online data supplement). Rise in [Ca 2ϩ ] o from 1.8 mmol/L to 2.4 mmol/L, and to 3.0 mmol/L enhanced I Ks by 27.9Ϯ8.3% and 43.8Ϯ11.2%, respectively, which were fully reversed by L-NAC (1 mmol/L) ( Figure 6C and online data supplement).
Discussion
NO has been shown to play important roles in the physiological regulation of Ca 2ϩ cycling of cardiomyocytes. 21 In this study, we demonstrate that Ca 2ϩ regulation of I Ks channel is another critical NO-dependent Ca 2ϩ cycling system based on the following findings: (1) a NO donor mimicked Ca 2ϩinduced I Ks enhancement; (2) a NOS inhibitor abolished I Ks enhancement by Ca 2ϩ ; (3) a NO scavenger also abolished Ca 2ϩ -induced I Ks enhancement; and (4) changes in I Ks kinetics caused by a NO donor were very similar to those by Ca 2ϩ .
To examine the mechanism underlying Ca 2ϩ -sensitivity of I Ks , we increased [Ca 2ϩ ] i by using a Ca 2ϩ -ionophore, A23187, and recorded whole-cell I Ks in the perforated patch configuration. This recording configuration is preferred to study Ca 2ϩ regulation of I Ks , because it prevents wash-out of the intracellular signal transduction machinery. The peak [Ca 2ϩ ] i was increased from 0.97Ϯ0.03 mol/L in the control state to 1.24Ϯ0.03 mol/L by A23187 at 0.1 mol/L and to 1.52Ϯ0.09 mol/L by A23187 at 2 mol/L, whereas APD and I Ks were barely affected by A23187 at 0.1 mol/L and maximally changed by A23187 at 2 mol/L. Thus, the threshold of [Ca 2ϩ ] i to modulate APD and I Ks appears to be between 1.24 and 1.52 mol/L, which is well within the range where [Ca 2ϩ ] i physiological varies in cardiac myocytes. The changes in [Ca 2ϩ ] i reached the stable level at 5 minutes after application of A23187 (see online data supplement), which is similar to the time course of changes in APD and I Ks by A23187, further supporting that effects of APD and I Ks by A23187 were attributable to changes in [Ca 2ϩ ] i .
In addition to Ca 2ϩ -induced enhancement of I Ks , rise in [Ca 2ϩ ] i causes Ca 2ϩ -induced inactivation of I Ca,L . 13, 14 To understand the feedback system of Ca 2ϩ entry, it is important to know relative contributions of Ca 2ϩ -induced I Ks enhancement and I Ca,L inactivation to the Ca 2ϩ -induced APD shortening. In the present study, at a low stimulation rate, both I Ks enhancement and I Ca,L inactivation contribute to the Ca 2ϩ -induced APD shortening with a similar magnitude. However, at a high stimulation rate, A23187-induced APD shortening was reversed by 75% to 80% with chromanol 293B and only by 20% to 25% with nisoldipine. Thus, at a high stimulation rate, Ca 2ϩ -induced I Ks enhancement plays a dominant role in APD shortening. A23187-induced APD shortening was dependent on stimulation rate: the higher the stimulation was, the greater the A23187-induced APD shortening was. This result is consistent with a simulation study showing that I Ks underlies rate-dependent adaptation of APD at fast heart rates. 22 Fast pacing results in short diastolic intervals that prevent complete deactivation of I Ks , resulting in build-up of instantaneous I Ks repolarizing current. 22 In our study, elevated I Ks components at higher [Ca 2ϩ ] i may cause additional accumulation of the repolarizing current, resulting in the greater APD shortening in the presence of A23187.
We have previously demonstrated that I Ca,L is suppressed by NO via a cGMP-dependent pathway. 11 However, NOdependent modulation of I Ca,L appears not to play a significant role in the Ca 2ϩ -induced I Ca,L inactivation in our experiments, because neither a NO scavenger, L-NAC, nor a NOS inhibitor, SMTU, reversed the A23187-induced I Ca,L suppression (see online data supplement). Because I Ca,L channel inactivation is underlined by direct interaction of Ca 2ϩ /CaM with the I Ca,L channels 2,3 that is situated in a pathway upstream of Ca 2ϩ /CaM-dependent activation of NOS3, effects of NO on the I Ca,L channels may be masked by a direct effect of Ca 2ϩ /CaM. The finding that L-NAC and SMTU reversed A23187-induced APD shortening only partially may further implicate that a fraction of APD shortening caused by I Ca,L inactivation is insensitive to NO modulators.
It is also critical to know whether Ca 2ϩ -induced I Ks enhancement and resultant APD shortening act in physiological and/or pathological conditions of the hearts. To address this question, we used physiologically relevant Ca 2ϩ loading such as digoxin and rise in [Ca 2ϩ ] o. Digoxin, a selective blocker of Na ϩ /K ϩ -ATPase is known to increase [Ca 2ϩ ] i by indirectly enhancing activity of Na ϩ -Ca 2ϩ exchanger, and in fact in our study, digoxin increased both basal and peak [Ca 2ϩ ] i . Both application of digoxin and rise in [Ca 2ϩ ] o induced shortening of APD and enhancement of I Ks . APD shortening was partially reversed by a NO scavenger, L-NAC, and I Ks enhancement was fully reversed by L-NAC. Thus, Ca 2ϩinduced I Ks enhancement and resultant APD shortening appear to be one of the physiological and pathological regulators of I Ks , among other well-known regulators, such as ␤-adrenergic regulation. 23, 24 Because Ca 2ϩ enters in cells during the action potential plateau, changes in APD may affect the amount of Ca 2ϩ entry, and thereby [Ca 2ϩ ] i . 25 Indeed, Padmala and Demir reported that the 40% reduction in APD results in 60% reduction in Ca 2ϩ entry through I Ca,L , 23% reduction in peak [Ca 2ϩ ] i , and 18% reduction in diastolic [Ca 2ϩ ] i . 26 Thus, Ca 2ϩ -induced APD shortening potentially acts as a negative feedback system to maintain [Ca 2ϩ ] i within an appropriate range.
Cardiomyocytes express both NOS1 and NOS3. 19, 21 The finding that L-NIO, a relatively specific NOS3 inhibitor completely abolished I Ks enhancement by A23187, whereas SMTC, a relatively specific NOS1 inhibitor, barely affected it, strongly suggests that the activation of NOS3, rather than NOS1, is involved in the I Ks enhancement. NOS3 is activated via at least two distinct pathways, a CaM-dependent pathway and an Akt-dependent pathway. 17, 18 In the present study, Ca 2ϩ -dependent I Ks enhancement was blocked by a CaM inhibitor, W7, but was barely affected by an Akt inhibitor, SH-6, indicating that a CaM-dependent activation of NOS3 participates in this phenomenon. We have previously reported that I Ks is enhanced by intracellular Ca 2ϩ , which may be consequences of allosteric interaction of CaM rather than phosphorylation by CaM kinase II, because a CaM inhibitor, W7, but not a CaM kinase II inhibitor, KN62, inhibited the Ca 2ϩ -induced I Ks enhancement. 5 This hypothesis is supported by our immunoprecipitation-immunoblotting data that the elevation of [Ca 2ϩ ] i by A23187 switched the protein-protein interaction from NOS3-Cav-3 to NOS3-CaM. In cardiomyocytes, NOS1 and NOS3 have opposing actions in Ca 2ϩ cycling: NO released from NOS3 decreases [Ca 2ϩ ] i by suppressing the I Ca,L channel activities, whereas NO released from NOS1 increases [Ca 2ϩ ] i by activating ryanodine receptor type 2. 19, 21 The opposing actions of NOS1 and NOS3 in Ca 2ϩ cycling are critically dependent on their spatial confinement with effecter molecules: the ryanodine receptor type 2 and NOS 1 on endoplasmic reticulum and the I Ca,L channel and NOS3 on sarcolemma. 19, 21 The Ca 2ϩ -induced enhancement of I Ks can be observed in cell-free excised patch configuration, 6 implicating that the spatial confinement of NOS3 with the I Ks channel also takes place. Interestingly, the ␣ subunit of the I Ks channel, KCNQ1, has two potential binding sites for Ca 2ϩfree CaM (apo-CaM), an IQ motif and a ⌽ motif, in its intracellular C-terminal region. 27 Yeast two-hybrid assay also suggests that KCNQ1 associates with apo-CaM. 27 Thus, the changes in protein-protein interactions may occur in the membrane-delimited microdomains that involve Cav-3, NOS3, CaM, and KCNQ1. Because of participation of Cav-3, the microdomains are likely to be in the caveola. Although the I Ks channel has been suggested to colocalize with the ␤ 2 -adrenergic receptor that accumulates in caveolae, 28 the direct demonstration of localization of components of the I Ks channel, KCNQ1 and KCNE1, with the caveolae remains to be shown.
